Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.

about

Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.

Item

http://www.wikidata.org/entity/Q41103332

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Somatostatin Receptor Expressi ...... Combination with Pegvisomant.

@en

type

Item

label

Somatostatin Receptor Expressi ...... Combination with Pegvisomant.

@en

prefLabel

Somatostatin Receptor Expressi ...... Combination with Pegvisomant.

@en

P1476

Somatostatin Receptor Expressi ...... n Combination with Pegvisomant

@en

P2093

Aart Jan van der Lely

http://www.w3.org/2001/XMLSchema#string

Alof H G Dallenga

http://www.w3.org/2001/XMLSchema#string

Leo J Hofland

http://www.w3.org/2001/XMLSchema#string

Sanne E Franck

http://www.w3.org/2001/XMLSchema#string

Sebastian J C M M Neggers

http://www.w3.org/2001/XMLSchema#string

P2860

Interrelationships between somatostatin sst2A receptors and somatostatin-containing axons in rat brain: evidence for regulation of cell surface receptors by endogenous somatostatin

Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.

Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial.

Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis.

Expert consensus document: A consensus on the medical treatment of acromegaly.

Modulation of pituitary somatostatin receptor subtype (sst1-5) messenger ribonucleic acid levels by changes in the growth hormone axis.

Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.

A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy.

The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status.

Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment.

P304

44-53

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000448429

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P50

Federico Gatto

Joop A M J L Janssen

A P Nagtegaal

P577

2016-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27455094

http://www.w3.org/2001/XMLSchema#string

P932

5475231

http://www.w3.org/2001/XMLSchema#string